Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Promethera Biosciences SA NV

www.promethera.com

Latest From Promethera Biosciences SA NV

Bookmark
  • Analysis

Venture Funding Deals: Takeda's Phathom Raises $140m In Crossover Round For GERD Program

By Deanna Kamienski, Beth Detuzzi and Maureen Riordan

AgomAb, CinCor and Confo Therapeutics secure Series A financing, while AlloVir closes a $121m Series B and more venture financing in April and May.

Deals Financing
Bookmark
  • News

Finance Watch: Q1 Numbers Suggest A Brisk VC Deal Pace For Cell And Gene Therapies In 2019

By Mandy Jackson

An Alliance for Regenerative Medicine (ARM) report shows big Q1 numbers for venture capital and partnership deals. Also, mid-May VC deals surge globally across therapeutic areas, Biogen pushes back against a bargain-hunting investor and recent public company financings.

Financing Regenerative Medicine
Bookmark
  • News

Finance Watch: A One-Time Treatment For Heart Disease? Verve Raises $58.5m To Give It A Try

By Mandy Jackson

Private Company Edition: With academic muscle, Google cash and nanoparticles, and various CRISPR licenses, Verve will develop gene-editing therapies for coronary heart disease prevention. Also, Vividion raises an $82m series B and two Belgian companies bring in $77.8m in VC cash.

Financing StartUps and SMEs
Bookmark
  • News

Asian Investors Bankroll €40m Promethera Biosciences Series D

By Mike Ward

Liver disease-focused Belgian cell therapy biotech Promethera Biosciences closes a €39.7m ($44.4m) Series D round co-led by new Japanese investors Itochu Corporation and Shinsei Capital Partners. Asian investors now own about 44% of company.

Commercial Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Alias(es)
  • Promethera Biosciences
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Promethera Biosciences SA NV
  • Senior Management
  • John Tchelingerian, PhD, Pres. & CEO
    Mutsuki Takano, CFO
    Etienne Sokal, MD, PhD, CMO & CSO
    Henrik L Luessen, PhD, CBO
  • Contact Info
  • Promethera Biosciences SA NV
    Phone: (32) (0)10 39 43 00
    Rue Granbonpré, 11
    Watson & Crick
    Mont-Saint-Guibert, B-1435
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By